Cargando…
The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells
BACKGROUND: Although patient-sourced cardiac stem cells repair damaged myocardium, the extent to which medical co-morbidities influence cardiac-derived cell products is uncertain. Therefore, we investigated the influence of atherosclerotic risk factors on the regenerative performance of human cardia...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880978/ https://www.ncbi.nlm.nih.gov/pubmed/27225482 http://dx.doi.org/10.1186/s13287-016-0321-4 |
_version_ | 1782433885743742976 |
---|---|
author | Mayfield, Audrey E. Fitzpatrick, Megan E. Latham, Nicholas Tilokee, Everad L. Villanueva, Melanie Mount, Seth Lam, Bu-Khanh Ruel, Marc Stewart, Duncan J. Davis, Darryl R. |
author_facet | Mayfield, Audrey E. Fitzpatrick, Megan E. Latham, Nicholas Tilokee, Everad L. Villanueva, Melanie Mount, Seth Lam, Bu-Khanh Ruel, Marc Stewart, Duncan J. Davis, Darryl R. |
author_sort | Mayfield, Audrey E. |
collection | PubMed |
description | BACKGROUND: Although patient-sourced cardiac stem cells repair damaged myocardium, the extent to which medical co-morbidities influence cardiac-derived cell products is uncertain. Therefore, we investigated the influence of atherosclerotic risk factors on the regenerative performance of human cardiac explant-derived cells (EDCs). METHODS: In this study, the Long Term Stratification for survivors of acute coronary syndromes model was used to quantify the burden of cardiovascular risk factors within a group of patients with established atherosclerosis. EDCs were cultured from human atrial appendages and injected into immunodeficient mice 7 days post-left coronary ligation. Cytokine arrays and enzyme linked immunoassays were used to determine the release of cytokines by EDCs in vitro, and echocardiography was used to determine regenerative capabilities in vivo. RESULTS: EDCs sourced from patients with more cardiovascular risk factors demonstrated a negative correlation with production of pro-healing cytokines (such as stromal cell derived factor 1α) and exosomes which had negative effects on the promotion of angiogenesis and chemotaxis. Reductions in exosomes and pro-healing cytokines with accumulating medical co-morbidities were associated with increases in production of the pro-inflammatory cytokine interleukin-6 (IL-6) by EDCs. Increased patient co-morbidities were also correlated with significant attenuation in improvements of left ventricular ejection fraction. CONCLUSIONS: The regenerative performance of the earliest precursor cell population cultured from human explant tissue declines with accumulating medical co-morbidities. This effect is associated with diminished production of pro-cardiogenic cytokines and exosomes while IL-6 is markedly increased. Predictors of cardiac events demonstrated a lower capacity to support angiogenesis and repair injured myocardium in a mouse model of myocardial infarction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13287-016-0321-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4880978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48809782016-05-27 The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells Mayfield, Audrey E. Fitzpatrick, Megan E. Latham, Nicholas Tilokee, Everad L. Villanueva, Melanie Mount, Seth Lam, Bu-Khanh Ruel, Marc Stewart, Duncan J. Davis, Darryl R. Stem Cell Res Ther Research BACKGROUND: Although patient-sourced cardiac stem cells repair damaged myocardium, the extent to which medical co-morbidities influence cardiac-derived cell products is uncertain. Therefore, we investigated the influence of atherosclerotic risk factors on the regenerative performance of human cardiac explant-derived cells (EDCs). METHODS: In this study, the Long Term Stratification for survivors of acute coronary syndromes model was used to quantify the burden of cardiovascular risk factors within a group of patients with established atherosclerosis. EDCs were cultured from human atrial appendages and injected into immunodeficient mice 7 days post-left coronary ligation. Cytokine arrays and enzyme linked immunoassays were used to determine the release of cytokines by EDCs in vitro, and echocardiography was used to determine regenerative capabilities in vivo. RESULTS: EDCs sourced from patients with more cardiovascular risk factors demonstrated a negative correlation with production of pro-healing cytokines (such as stromal cell derived factor 1α) and exosomes which had negative effects on the promotion of angiogenesis and chemotaxis. Reductions in exosomes and pro-healing cytokines with accumulating medical co-morbidities were associated with increases in production of the pro-inflammatory cytokine interleukin-6 (IL-6) by EDCs. Increased patient co-morbidities were also correlated with significant attenuation in improvements of left ventricular ejection fraction. CONCLUSIONS: The regenerative performance of the earliest precursor cell population cultured from human explant tissue declines with accumulating medical co-morbidities. This effect is associated with diminished production of pro-cardiogenic cytokines and exosomes while IL-6 is markedly increased. Predictors of cardiac events demonstrated a lower capacity to support angiogenesis and repair injured myocardium in a mouse model of myocardial infarction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13287-016-0321-4) contains supplementary material, which is available to authorized users. BioMed Central 2016-05-26 /pmc/articles/PMC4880978/ /pubmed/27225482 http://dx.doi.org/10.1186/s13287-016-0321-4 Text en © Mayfield et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Mayfield, Audrey E. Fitzpatrick, Megan E. Latham, Nicholas Tilokee, Everad L. Villanueva, Melanie Mount, Seth Lam, Bu-Khanh Ruel, Marc Stewart, Duncan J. Davis, Darryl R. The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells |
title | The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells |
title_full | The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells |
title_fullStr | The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells |
title_full_unstemmed | The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells |
title_short | The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells |
title_sort | impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880978/ https://www.ncbi.nlm.nih.gov/pubmed/27225482 http://dx.doi.org/10.1186/s13287-016-0321-4 |
work_keys_str_mv | AT mayfieldaudreye theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT fitzpatrickmegane theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT lathamnicholas theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT tilokeeeveradl theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT villanuevamelanie theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT mountseth theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT lambukhanh theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT ruelmarc theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT stewartduncanj theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT davisdarrylr theimpactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT mayfieldaudreye impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT fitzpatrickmegane impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT lathamnicholas impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT tilokeeeveradl impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT villanuevamelanie impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT mountseth impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT lambukhanh impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT ruelmarc impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT stewartduncanj impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells AT davisdarrylr impactofpatientcomorbiditiesontheregenerativecapacityofcardiacexplantderivedstemcells |